key: cord-0707797-a8s5x0w2
authors: Buil, Jochem B.; Oliver, Jason D.; Law, Derek; Baltussen, Tim; Zoll, Jan; Hokken, Margriet W. J.; Tehupeiory-Kooreman, Marlou; Melchers, Willem J. G.; Birch, Mike; Verweij, Paul E.
title: Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance
date: 2022-03-01
journal: Emerging microbes & infections
DOI: 10.1080/22221751.2022.2034485
sha: 88136a5ce294c7b968d1610e104b11c1c7cb3b5d
doc_id: 707797
cord_uid: a8s5x0w2

Olorofim (F901318) is a new antifungal currently under clinical development that shows both in vitro and in vivo activity against a number of filamentous fungi including Aspergillus fumigatus. In this study, we screened A. fumigatus isolates for intrinsic olorofim-resistant A. fumigatus and evaluated the ability of A. fumigatus to acquire an olorofim-resistant phenotype. No intrinsic resistance was found in 975 clinical A. fumigatus isolates. However, we found that isolates with increased olorofim MICs (> 8 mg/L) could be selected using a high number of conidia and olorofim exposure under laboratory conditions. Assessment of the frequency of acquired olorofim resistance development of A. fumigatus was shown to be higher than for voriconazole but lower than for itraconazole. Sequencing the PyrE gene of isogenic isolates with olorofim MICs of >8 mg/L identified various amino acid substitutions with a hotspot at locus G119. Olorofim was shown to have reduced affinity to mutated target protein dihydroorotate dehydrogenase (DHODH) and the effect of these mutations was proven by introducing the mutations directly in A. fumigatus. We then investigated whether G119 mutations were associated with a fitness cost in A. fumigatus. These experiments showed a small but significant reduction in growth rate for strains with a G119V substitution, while strains with a G119C substitution did not exhibit a reduction in growth rate. These in vitro findings were confirmed in an in vivo pathogenicity model.

It is estimated that around 250,000 people worldwide suffer from invasive aspergillosis annually [1] . Patients at risk include those with neutropenia and in recent years cases have been increasingly observed in intensive care unit patients, including those with severe influenza or coronavirus infection [2] [3] [4] [5] [6] . The triazoles voriconazole and isavuconazole are the recommended first line agents for the management of invasive aspergillosis [7, 8] . The use of other registered antifungal agents such as liposomal amphotericin B is limited due to toxicity while the echinocandins exhibit lower efficacy against Aspergillus compared to the triazoles [9, 10] . Furthermore, the triazoles are currently the only agents that can be administered orally. However, the use of triazoles is threatened by the emergence of azole resistance in Aspergillus fumigatus [11] , which has now been reported globally [12, 13] . Voriconazole resistance in A. fumigatus infection was associated with a near doubling of mortality at day 42 compared to voriconazole susceptible infection in patients that were treated with voriconazole [14] . Azole resistance is mainly driven by environmental exposure of A. fumigatus to azole fungicides, which selects for fungicide resistance mutations that confer cross resistance to medical triazoles [15] . In regions with environmental resistance, any patient may present with azole-resistant invasive aspergillosis that complicates diagnosis and successful therapy. Thus, there is an urgent need for new antifungal agents with efficacy against both azole-susceptible and azole-resistant A. fumigatus infection.

Olorofim (F901318) is a new antifungal currently under clinical development that shows activity against a number of filamentous fungi including A. fumigatus. It belongs to a new orotomide class of antifungals and acts by selective inhibition of fungal dihydroorotate dehydrogenase (DHODH), an essential enzyme within the de novo pyrimidine biosynthesis pathway [16, 17] . The spectrum of activity of olorofim includes Aspergillus species including cryptic Aspergillus species and azole-resistant Aspergillus isolates [18] [19] [20] [21] [22] [23] [24] [25] , Lomentospora prolificans, Scedosporium species [17, [26] [27] [28] [29] [30] , agents of endemic mycoses such as Coccidioides species, Histoplasma species, Sporothrix schenckii and Blastomyces species [17, 31] . Furthermore, in vitro studies show activity against Madurella mycetomatis [32] , Microascus/Scopulariopsis, Penicillium, Paecilomyces, Purpureocillium, Rasamsonia, Talaromyces species [17, 33, 34] , dermatophytes [34] and some Fusarium species [35] . The in vitro activity was confirmed in in vivo models for pulmonary aspergillosis with azole-susceptible and azole-resistant isolates of A. fumigatus [17, 25] , in a murine model of disseminated A. terreus aspergillosis [36] , a murine model of chronic granulomatous disease infected with A. fumigatus, A. nidulans, and A. tanneri [21] and in a murine model of central nervous system coccidioidomycosis [31] .

Antifungal drug resistance may develop through genetic variation that is created by the fungus to enable its adaptation to stress factors in its environment. Although drug exposure is not relevant to the development of resistance mutations per se, antifungal drug selection pressure is critical to create dominance of resistant cells within a population of fungal cells. The risk of resistance selection to a new class of antifungal drugs such as the orotomides will depend on the frequency of spontaneous mutations that confer an orotomide-resistant phenotype and the extent of selection pressure through patient therapy. In this study, we screened for intrinsic olorofim-resistant A. fumigatus, evaluated the ability of A. fumigatus to develop an olorofim-resistant phenotype, and characterized underlying olorofim resistance mechanisms, including the effect of mutated DHODH on olorofim affinity and the impact of resistance mutations on virulence in a mouse model of disseminated aspergillosis. Lastly, the effect of mutated DHODH on conferring olorofim resistance in A. fumigatus was proven by introducing the mutation in a wildtype A. fumigatus strain.

We screened 976 clinical A. fumigatus isolates that were cultured between 2015 and 2017 for non-wildtype olorofim phenotypes. Inoculum with a density of approximately 0.5 McFarland was prepared in sterile 0.9% NaCl with 0.1% Tween 20 and one drop of 25 µl was used to inoculate an agar plate (RPMI1640 (Gibco) with 2% glucose (Merck), buffered with MOPS (Sigma)) containing 0.125 mg/L olorofim. An agar plate containing only RPMI1640 with 2% glucose agar was used as growth control. Olorofim MIC-testing was performed on isolates growing on the agar plate containing olorofim. If routine susceptibility results indicated resistance to voriconazole or itraconazole, the Cyp51A gene was subsequently sequenced.

Susceptibility testing was performed using the EUCAST method for susceptibility testing of moulds E.Def.9.3.1 (EUCAST.org). Olorofim pure powder was obtained from F2G (Manchester, United Kingdom). Stock solutions of olorofim were prepared in DMSO (Boom BV). 96-wells plates with 2-fold dilutions of olorofim were prepared in RPMI1640 with 2% glucose and buffered with MOPS. The olorofim concentration range used was 0.016-8 mg/ liter. Inoculum was prepared in sterile 0.9% NaCl with 0.1% Tween 20. Spores were harvested from mature culture and the suspension was adjusted to 80-82% transmission at 530 nm (Spectrofotometer Genesys 20) to create a 1-4.2 × 10 6 CFU/ml spore suspension [37] . Inocula were added to the 96-well plates to create a final concentration of 2-5 × 10 5 CFU/ml in each well. The inoculated plates were incubated for 48 h at 35°C. MIC was defined as the lowest concentration without visible growth.

Six A. fumigatus isolates (ATCC 204305, AZN8196 [38] , V052-35 (TR 34 /L98H) [38] , V139-36, V180-37 [39] and V254-51) were used for the olorofim resistance induction experiment. Strains were confirmed to be A. fumigatus based on the Beta-tubulin sequence. Sabouraud dextrose broth containing chloramphenicol (SAB-c) was inoculated and cultures were grown at 28°C. Spores were harvested in sterile saline with 0.1% tween 20 and the inoculum was transferred to a sterile vial. The spore suspension was adjusted to 1 × 10 9 spores/mL using an hemocytometer. One mL spore suspension was added to a 90 mm agar plate containing RPMI 1640 + 2% glucose (1.5% agar) containing 0.5 mg/L olorofim. Cultures were grown at 28°C

. Isolates that grew on the olorofim containing plates were subcultured on SAB-c for subsequent MIC testing and DNA isolation.

Six A. fumigatus isolates (ATCC 204305, AZN8196, V052-35 (TR34/L98H), V139-36, V180-37 and V254-51) were used for the olorofim resistance induction experiment ( Table 2) . SAB-c was inoculated using a single spore isolated from the six parent strains and cultures were grown at 28°C. Spores were harvested in sterile saline with 0.1% tween 20 and the inoculum was transported to a sterile vial. The spore suspension was adjusted to 1 × 10 9 spores/mL using an hemocytometer. One mL spore suspension was added to a 90 mm agar plate containing RPMI 1640 + 2% glucose (1,5% agar) containing either 0.5 mg/L olorofim, 4 mg/L voriconazole (Sigma) or itraconazole (Sigma) 8 mg/L. These concentrations were chosen as these were the concentrations which are 2 dilutions higher that the concentration that inhibits 100% of wildtype A. fumigatus isolates [40] . Cultures were grown at 28°C. Isolates that grew on the olorofim containing plates were subcultured on SAB-c for subsequent MIC testing and DNA isolation. The resistance rate was calculated by dividing the number of retrieved resistant colonies by the number of inoculated spores and the mean of 5 experiments was used for comparison. Differences in resistance frequency between olorofim and itraconazole or voriconazole were tested for significance using the student T-test. Statistical significance was defined as a P-value of ≤0.05 (twotailed). To confirm the resistant rates, a second experiment was performed in another laboratory. Spore stocks of A. fumigatus strain Af293 were prepared and inoculated onto yeast nitrogen base with glucose agar (YNBG) containing 0.25 mg/L olorofim. A total of 8 × 10 9 spores were inoculated into 12 × 100 ml YNBGagar plates containing 0.25 mg/L olorofim that were subsequently incubated for 5 days at 35°C. Colonies growing on drug-containing plates were subcultured again on YNBG-containing 0.25 mg/L olorofim to confirm resistance.

The PyrE gene of all isolates from parent strain Af293 were sequenced as previously described using primers AFDseq-F2 and AFDseq-R2 [18] . PyrE amino acid sequences of olorofim-resistant strains were compared to the amino acid sequence of the wildtype parent strains. As these and the earlier pilot experiments showed only amino acid substitutions at locus G119 without mutations at other loci in PyrE, we sequenced only part of the PyrE gene for the other strains. This part of the A. fumigatus PyrE gene was sequenced using primer PyrE_G119_Fwd: AGTAAAGGAGG-CACCCAAGAAAGCTGG and PyrE_G119_Rev: GCCAATGGGGTTGTTGAGCGTATACCC.

We randomly selected 39 olorofim-resistant strains from the resistant frequency analysis.

The cloning of A. fumigatus DHODH (89-531) cDNA into protein expression vector pET44 yielding pET44AFD was described previously [17] . For the preparation of mutated protein, this plasmid was mutated at codon 119 using the Phusion Site-Directed Mutagenesis kit (Thermo Scientific). PCR reactions were set up with Phusion HSII polymerase, pET44AFD as a template, with one constant primer (AFDSDM_R1; CCTCTTCCGCGTCGGGATAA) and a variable that had a single codon change (CGCATCATATTxyzGTGGAAGCTCT).

The sequence of xyz (GGT in wild type) was: GTT for G119V; GCT for G119A; AGT for G119S; TGT for G119C. The PCR product representing a linear version of pET44AFD with the mutation present was ligated using T4 DNA ligase and transformed into Max Efficiency DH5α competent cells (Thermo Fisher). Sequencing confirmed the desired mutations were present. The constructs were transformed into E. coli BL21 (DE3) cells (Merck) and the mutant proteins were expressed and purified according to the protocol described by Oliver et al [17] . DHODH assays were set up in the presence and absence of olorofim at concentrations between 0.008-100 µM. Assays were carried out in 50 mM Tris HCl pH8, 150 mM KCl, 10% (wt/vol) glycerol, and 0.1% (wt/ vol) Triton X-100 in the presence of 1 mM L-dihydroorotic acid, 0.05 mM coenzyme Q2 and 0.1 mM 2,6-dichloroindophenol as a redox indicator. The reaction was followed by absorbance at 600 nm and reaction velocities used to construct IC50 curves [17] . Curves were fitted in GraphPad Prism using variable slope (four parameters) on log transformed data.

To prove that G119 mutations are resulting in increased olorofim MICs we introduced the G119C mutation in strain MFIG001 [41] as previously described [42] . In short, protoplasts were generated by inoculation of approximately 1 × 10 6 fresh conidia in Yeast extract Glucose medium (YG; 0.5% yeast extract, 2% glucose) for 16 h at 37°C shaking at 120 rpm. Mycelia were harvested by filtration and resuspended in YG with protoplasting buffer (5 g Vinotaste in 50 mL 1M KCl and 0.1 M Citric Acid added to 50 mL YG) and reincubated for 4 h at 37°C shaking at 100 rpm. Then protoplast was washed 3 times in 0.6 M KCl and 50 mM CaCl 2 and the protoplast concentration was adjusted and diluted to approximately 1 × 10 6 protoplasts. A PAM site close to the G119 locus was selected with an adjacent 20 nucleotide protospacer that covers the G119 locus using a web-based guide RNA designing tool EuPaGDT [43] . The genome sequence of A.

fumigatus A1163 (Aspergillus_fumigatu-sa1163.ASM15014v1) was manually uploaded to EuPaGDT to design gRNAs to the pyrE locus. The program was carried out with the default settings and the crRNA with the highest QC score closest to the target integration was selected for transformation. A single stranded (ss) DNA repair template was selected that covered 50 nucleotides on both sites of the protospacer and PAM site ( Figure s1 ) that contains a synonymous point mutation in the PAM site and the T > G mutation in the G119 locus resulting in GGT (Glycine) to TGT (Cysteine) transformation.

Alt-R® CRISPR-Cas9 tracrRNA, Alt-R® CRISPR-Cas9 crRNA, Alt-R® S.p. Cas9 Nuclease and ssDNA repair template were ordered from Integrated DNA Technologies. Ribonucleoprotein (RNP) complex was assembled in vitro in Nuclease-Free IDTE buffer. RNP complex, the ssDNA repair template and PEG buffer (60% wt/vol PEG3350, 50 mM CaCl2, 450 mM Tris-HCl, pH 7.5) were mixed with 50 µl of the 1 × 10 6 /ml protoplast and incubated on ice for 50 min. Then 1 mL of PEG 3350 was added to the solution and incubated for another 25 min at 20°C. The solution was incubated on five yeast extract peptone dextrose (YPD) agar plates and incubated for 48 h. Single colonies were subcultured on SDA slants and screened for resistance by spotting 2 µL containing 100-500 conidia on RPMI1640 2% glucose agar containing 0.125 mg/L olorofim and RPMI1640 2% glucose agar without olorofim as growth control. Five isolates showing prominent growth after 48 h were selected and further analyzed by olorofim MIC testing and sequencing of the pyrE G119 hotspot as described earlier.

To study the radial growth rate, we randomly selected five olorofim-resistant isolates, two from strain AZN8196 (AZN8196_OLR1, AZN8196_OLR2) and three from strain Af293 (Af293_OLR5, Af293_OLR7, and Af293_OLR9) from the initial induction experiments and compared the radial growth rate to the wildtype parent strain. The strains were chosen as these strains harboured the most common amino acid substitutions G119C, G119V and G119S. We assessed the growth by measuring the colony diameters in the horizontal axis and vertical axis once every 24 h for a period of 5 days. We used an initial inoculum of 2 × 10 2 spores, quantified with an hemocytometer for all strains and inoculated the spores in the middle of a 90 mm petri dish with Yeast Nitrogen Base with glucose. We did three independent experiments per strain and reported the mean of the three experiments. Differences in growth rate in mm/day at day 5 between wildtype and olorofim-resistant strains were tested for significance using the student T-test. Statistical significance was defined as a Pvalue of ≤0.05 (two-tailed).

Assessment of the pathogenicity of olorofimresistant progeny compared to strain AZN8196 and Af293

To study the virulence of isolates with PyrE aminoacid substitution, we assessed the survival of these isolates in a murine model of disseminated aspergillosis and compared the survival to their wildtype parent strains. Ideally, truly isogenic isolates are used for such experiments. However, the selected isolates were selected for olorofim resistance on a plate and only the PyrE gene was sequenced and we thus cannot exclude amino acid substitutions elsewhere in the genome. To exclude effects of such additional substitutions we used five separately selected olorofimresistant strains to perform the experiments. CD-1 mice (Charles River Laboratories, Margate, UK) were immunosuppressed 3 days prior to infection with cyclophosphamide administered at 200 mg/kg subcutaneously. Inoculum was prepared for A. fumigatus strains AZN8196, AZN8196_OLR1, AZN8196_OLR2, Af293, Af293_OLR5, Af293_OLR7, and Af293_OLR9. Mice were infected by intravenous administration of 0.2 mL conidial suspension. An inoculum of approximately 5 × 10 5 CFU/mL was used for strains AZN8196, AZN8196_OLR1, AZN8196_OLR2 and an inoculum of approximately 2 5 × 10 7 CFU/mL was used for strains Af293, Af293_OLR5, Af293_OLR7, and Af293_OLR9 resulting in 1 × 10 5 CFU/mouse and 5 × 10 6 CFU/mouse respectively. These inocula were chosen as those are the LD 90 doses that were previously determined for these specific A. fumigatus strains [44, 45] . The concentration of conidia was adjusted using a hemocytometer and confirmed by quantitative culture on SDA. Actual and intended inoculum levels are listed in table S2. Eight mice were inoculated with all strains. Mice were monitored for survival for 10 days and euthanized when they demonstrated high weight loss, signs of sepsis or severe torticollis. Survival data were analyzed using GraphPad Prism (Version 5.3) and checked for significance using the Log-rank (Mantel-Cox) Test. Statistical significance was defined as a P-value of ≤0.05 (two-tailed).

A total of 976 clinical A. fumigatus isolates were screened for olorofim non-wildtypes on agar plates containing 0.125 mg/L olorofim. Only one isolate showed growth on the agar well supplemented with 0.125 mg/L olorofim (isolate V179-44). No growth on plates containing 0.125 mg/L olorofim was seen in the other 975 isolates.

Clinical A. fumigatus isolate (V179-44) was identified as possibly olorofim resistant and in vitro susceptibility testing using a spore suspension derived directly from the agar well supplemented with 0.125 mg/L of olorofim, showed an olorofim MIC of >8 mg/L. Susceptibility testing from the initial culture of strain V179-44 resulted in a wildtype olorofim MIC of 0.031 mg/L. Identification of the resistant isolate through beta-tubulin sequencing confirmed the conventional identification as A. fumigatus sensu strictu [46] . As we suspected selection of a colony with a spontaneous olorofim resistance mutation, we tried to replicate this observation. Inoculation of >1 × 10 9 spores of three A. fumigatus isolates (AZN8196, V052-35 and V139-36) on three 90 mm petri dishes with RPMI1620 agar supplemented with 2% glucose containing 0.5 mg/L olorofim, two olorofim-resistant A. fumigatus colonies were retrieved from parental strain AZN8196 (AZN8196_OLR1 and AZN8196_OLR2), three from V052-35 (V052-35_OLR1 to V052_OLR3) and 11 from V139-36 (V139-36_OLR1 to V139-36-OLR11).

Six A. fumigatus isolates (ATCC 204305, AZN8196, V052-35 (TR 34 /L98H), V139-36, V180-37 and V254-51) ( Table 1) were used for the resistance frequency experiment. A total of 131 olorofim non-wildtype strains were retrieved, all of which showed an olorofim MIC of >8 mg/L (Table S1 ). An olorofim resistance frequency of 1.3 × 10 −7 -6.9 × 10 −9 was observed ( Figure 1 ). The mean itraconazole resistance frequency was between 1.2 × 10 −6 and 3.3 × 10 −8 and the mean voriconazole resistance frequency was between 1.8 × 10 -8 and 2.0 × 10 -10 . Overall, the frequency of resistance was higher for itraconazole compared to olorofim, while voriconazole had the lowest frequency of resistance. The frequency of resistance of olorofim was significantly lower than itraconazole for strains AZN8196 and V254-51, while the frequency was not significantly lower for strains ATCC204305, V139-36 and V180-37. The frequency of voriconazole resistance was significantly lower compared with olorofim for strains ATCC204305, AZN8196, V139-36 and V254-51, while no significant differences were observed for strain V180-37. The second independent resistance frequency analysis using isolate Af293, which was cultured on yeast nitrogen base agar with glucose supplemented with 0.25 mg/L olorofim resulted in a mean frequency of olorofim resistance of 1.7 × 10 −9 , a rate comparable to the above experiments. A total of 11 isolates were retrieved from parent strain Af293 of which 10 had an olorofim MIC of >8 mg/L while one had a MIC of 0.25 mg/L (Table S1 ).

The target of olorofim has been identified as the pyrimidine biosynthetic enzyme DHODH, which in A. fumigatus is encoded by the pyrE gene. When sequencing the full pyrE gene of olorofim strains retrieved from parent strain Af293, we found mutations at locus G119 in 10 of 11 sequenced olorofim-resistant isolates. A single isolate with an olorofim MIC of 0.25 mg/L had a pyrE sequence identical to the parent Af293 strain. Subsequent analysis of a subset of 39 isolates from the resistance frequency analysis, showed that mutations that resulted in an amino acid substitution at G119 were present in 38/ 39 isolates. In total 7 isolates had a G119A amino acid substitution, while we found G119C (21 isolates), G119F (1 isolate), G119Y (1 isolates), G119S (11 isolates), and G119V (7 isolates) amino acid substitutions in the other isolates. One olorofim-resistant isolate harboured a H116P amino acid substitution in the PyrE gene ( Table 2) .

We investigated the effect that selected mutations at G119 had on the ability of olorofim to inhibit recombinant A. fumigatus DHODH. Recombinant DHODH with the amino acid substitutions G119A, G119V G119S and G119C showed significantly higher IC 50 values for olorofim compared to wildtype DHODH ( Figure 2) . The substitutions at G119 thus resulted in decreased inhibition of A. fumigatus DHODH by olorofim, confirming the olorofim resistance mechanism.

To further prove that the PyrE G119 mutations in A. fumigatus result in increased MICs to olorofim, we introduced the G119C mutation in A. fumigatus by a marker free CRISPR-Cas9 method in strain MFIG001 [41, 42] . MFIG001 is a strain deficient in Figure S2 ) and olorofim MICs of >8 mg/L.

As development of resistance is often associated with attenuated virulence [47] , we investigated the effects of olorofim resistance mutations on the fitness of A. fumigatus. To assess the impact of the substitution of G119 in the PyrE gene on fitness, we used in vitro radial growth experiments. Mean growth curves are shown in Figure 3 . The mean radial growth at day 5 of AZN8196_OLR1 (carrying the G119V mutation) was 30.7 mm, which was significantly different to the wildtype parent strain AZN8196 which had a mean growth of 40.0 mm (p < 0.001). The mean radial growth of AZN8196_OLR2 (G119C) was 35.8 mm, also slightly reduced compared to strain AZN8196 but not significantly (p = 0.06). The mean growth at day 5 was 42.7 mm for Af293, which was not significantly different compared with the mean growth at day 5 of strain Af293_OLR7 (G119C) (p = 0.349), which had a mean growth 43.2 mm. The mean 5-day growth of Af293_OLR5 (G119S) was slightly decreased compared to the parent at 39.5 mm (p = 0.0039). Once more the glycine to valine mutation had the greater effect on growth with Af293_OLR9 growing 28.8, 14.4 mm less than the parental strain (p = 0.0010). Thus, in two different A. fumigatus strains the G119V mutants grew significantly more slowly than the parental strain ( Figure 3 ).

A. fumigatus strains in an in vivo murine model

Although the radial growth rate experiments did not reveal significant fitness cost for two of the tested isolates, we wanted to confirm these observations in a neutropenic murine infection model. All strains demonstrated virulence with all animals succumbing to disease by 96 h post infection. Median survival times of animals infected with AZN8196, AZN8196_OLR1 (G119V) and AZN8196_OLR2 (G119C) were 68.13, 89.75 and 73.38 h after infection, respectively. Mice infected with AZN8196_OLR1 (G119V) survived significantly longer than those infected with their parent strain. There were no significant differences between mice infected with AZN8196_OLR2 and the parent strain (Figure 4(a) ). Median survival times of animals infected with Af293, Af293_OLR5 (G119S), Af293_OLR7 (G119C), and Af293_OLE9 (G119V) at a concentration of approximately 5 × 10 6 CFU/mouse were 45.25, 46.75, 48.25 and 55 h post infection, respectively. No difference in survival time was found between animals infected with Af293 and those infected with Af293_OLR5 (G119S) and Af293_OLR7 (G119C). However, Af293_OLR9 (G119V)-infected animals survived significantly longer than AF293-infected mice (Figure 4(b) ).

Whilst the other mutants tested appeared as virulent as their parental strains, the two G119V mutant strains generated from different parents survived for longer. This is consistent with the slower growth observed for these strains in the radial growth experiments. These strains appear less fit than the wild type both in vitro and in vivo.

Evaluation of a large collection of clinical A. fumigatus isolates showed that the olorofim resistance frequency is negligible and no cross resistance with azoles was detected. However, olorofim resistance can be selected for under laboratory conditions and is associated with point mutations at locus G119 of the PyrE gene. Such mutations confer a resistant olorofim phenotype (olorofim MICs >8 mg/L), which appeared to have variable effects on virulence.

Olorofim is a promising novel antifungal with in vitro and in vivo efficacy against A. fumigatus infection, including triazole-resistant cases. The drug is currently undergoing phase II evaluation for the treatment of patients with invasive fungal infections that cannot be managed with current agents. Screening of over 900 clinical A. fumigatus isolates showed intrinsic resistance is not identified, confirming the results from susceptibility testing of 1032 clinical A. fumigatus isolates from Denmark [18] .

Olorofim resistance in A. fumigatus has not been reported before. A previous evolution experiment involving 50 passages of A. fumigatus exposed to an olorofim concentration gradient, resulted only in a modest olorofim MIC increase. In contrast voriconazole generated a four-fold increase in MIC after only 15 passages [17] . In the present study, we observed the in vitro acquisition of olorofim resistance while screening for intrinsic resistance using an agar supplemented with olorofim. All strains that were screened for olorofim resistance using this method were inhibited on this olorofim-containing agar, except one isolate. The olorofim-containing agar well of this strain showed growth of a single colony, in contrast to the growth control that showed confluent growth of numerous colonies on the whole agar surface. Had the initial isolate been resistant, we would have also expected numerous colonies growing in the olorofim-containing agar similar to the growth control. The lack of this growth, together with the discrepant results from the susceptibility testing of the parental colony and the colony growing on the olorofim-containing agar led us to believe that the resistant isolate had acquired olorofim resistance while being cultured on olorofim-containing agar.

By using a high inoculum of 1 × 10 9 CFU/mL we found that isolates with increased olorofim MICs (> 8 mg/L) could indeed be selected confirming our previous observation. As we wanted to understand the implications of this observation, we assessed the frequency of resistance development of A. fumigatus to olorofim and compared this frequency to other clinically used triazoles. We have chosen itraconazole and voriconazole as comparator agents as resistance development has been described in patients receiving long-term therapy for (cavitating) chronic pulmonary aspergillosis (CPA) but not in patients treated for acute invasive aspergillosis [48, 49] . We found that the resistance frequency of itraconazole was higher than the resistance frequency found for voriconazole. Similar observations are seen in the treatment of patients with CPA where the rate of emergence of azole resistance during therapy was 13% for itraconazole and 5% for voriconazole [50] . Differences in resistance frequency between itraconazole and voriconazole may be explained by the fact that almost all azole resistance associated substitutions reported in the Cyp51A gene result in itraconazole MICs above 4 mg/L, while only few substitutions result in highlevel resistance to voriconazole [51] . The finding of spontaneous olorofim resistance mutations is not surprising, but the frequency appears to be relatively low. The conditions that enable in vivo selection of olorofim resistance may be similar to those for triazole resistance; a setting of a high number of replicating fungal cells and chronic drug exposure. Such conditions may be present in patients with cavitary pulmonary lesions, such as aspergilloma and CPA but are unlikely in patients with acute invasive aspergillosis. However, as there are currently no alternative antifungal agents available for treatment of patients with triazole-resistant CPA that can be administered orally, olorofim represents a promising treatment option for this patient group that requires further clinical evaluation.

Importantly, in vivo selection of resistance mutations during treatment is not observed in patients treated for invasive aspergillosis. Triazole resistance in acute invasive aspergillosis is caused by inhalation of triazole-resistant A. fumigatus conidia that have developed resistance in the environment through exposure to azole fungicides, which occurred over several decades of exposure [15] . Agents that inhibit DHODH as mode of action are currently not used for crop protection; to prevent a similar scenario to environmental triazole resistance selection, the use of similar mode of action compounds for medical and environmental applications should be avoided.

DHODH is an essential enzyme in the de novo pyrimidine biosynthesis pathway, and disruption of this pathway results in attenuated virulence in A. fumigatus [52] . Similar observations are reported in other fungal species like Candida albicans, Cryptococcus neoformans and Histoplasma capsulatum and the necessity of an undisrupted pyrimidine biosynthesis pathway is demonstrated in both in vitro and in vivo models [53] [54] [55] . As DHODH, the product of the pyrE gene, is the enzyme target of olorofim action, we hypothesized that the most likely target of resistance is the pyrE gene [17] . Indeed, sequencing the PyrE gene of isolates with olorofim MICs of >8 mg/L identified various amino acid substitutions. A homology model of the A. fumigatus DHODH predicted a potential binding mode for olorofim [17] .

Locus G119, located within this binding site was identified as a specific hotspot for olorofim resistance in A. fumigatus as 48/49 sequenced isolates had amino acid substitutions at G119. A single isolate had an amino acid substitution at position H116 which was predicted as a key residue for olorofim binding [17] . The effect on olorofim susceptibility of mutations in PyrE at locus G119 was proven by both olorofim inhibition assay of mutant recombinant DHODH and by introducing the PyrE G119C mutation directly in A. fumigatus.

It remains uncertain whether locus G119 will also be the main mechanism of resistance if olorofimresistant pyrE isolates eventually emerge in clinical practice. Preliminary data shows that several translation factors may also play a role in olorofim susceptibility. A translation factor knockouts library screen revealed that deletion of HapB, AreA, DevR results in reduced susceptibility compared to WT isolates while deletion of transcription factor AcdX results in hypersensitivity [56] . However, similar in vitro resistance induction experiments were performed for triazole resistance in A. fumigatus. The mutations found in these in vitro experiments, like the amino acid substitutions at locus G54 and locus M220 in the Cyp51A gene can also be found in isolates retrieved from patients with CPA who are treated for long periods with triazoles, indicating that such in vitro experiments may predict the resistance mechanisms that can be found through clinical use [57, 58] .

As development of antifungal resistance is often associated with attenuated virulence [47] , we investigated whether amino acid substitutions in pyrE at locus G119 mutations were associated with a fitness cost in A. fumigatus. Analysis of A. fumigatus with disrupted chsC and chsG which encode Class III chitin synthases, showed a reduced colony radial growth rate compared to the wildtype strain. Subsequent assessment of pathogenicity in neutropenic mice showed a reduction in mortality in the mice inoculated with a chsC and chsG disrupted strain compared to the wildtype isolates [59] . Similar correlations between growth rate and virulence were observed when the growth rate of A. fumigatus was assessed in 96-wells plates using the optical density as indicator for growth rate [45] . To understand whether PyrE amino-acid substitutions influence fitness of A. fumigatus which may be extrapolated to in vivo pathogenicity, we analyzed the radial growth rate of five isolates with PyrE substitutions. These experiments showed a small but significant reduction in growth rate for strains with a G119V substitution (strain AZN8196_OLR1 and Af293_OLR9), while strains with a G119C substitution did not exhibit a reduction in growth rate. These in vitro findings were confirmed in the in vivo pathogenicity model whereas no significant difference in survival was observed for isolates with a G119C amino acid substitution (isolates AZN8196_OLR2 and Af293_OLR7). These results indicate that the amino acid substitution affects the binding of olorofim to DHODH but may not affect the function of DHODH itself and the effect on DHODH function is dependent on the underlying amino acid substitution. However, a limitation of this observation is the low number of isolates that were tested. Furthermore, compensatory evolution has been shown to occur in triazole-resistant A. fumigatus isolates when cultured in azole-free conditions, indicating that a potential fitness cost can be overcome [60] . However, population dynamics such as competition with other (wildtype) genotypes and selection pressure will ultimately determine which genotype will become dominant.

Olorofim represents an important new treatment option for patients with difficult to treat invasive fungal infections, including triazole-resistant A. fumigatus infection. Our study provides insights into one mechanisms and potential dynamics of olorofim resistance, which will help to prevent and manage resistance selection in various patient groups. Such insights are critical to antifungal stewardship and to safeguard its prolonged use in clinical practice.

Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi

Influenza-associated aspergillosis in critically ill patients

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients

Pulmonary aspergillosis in critically ill patients with Coronavirus disease 2019 (COVID-19)

Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside

Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B. Clin Infect Dis

Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis

Trends in azole resistance in Aspergillus fumigatus, the Netherlands

Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands

Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective Cohort study

Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis

Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

Olorofim susceptibility testing of 1423 Danish mould isolates 2018-2019 confirms uniform and broad-spectrum activity

Effect of the novel antifungal drug F901318 (olorofim) on growth and viability of Aspergillus fumigatus

EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs

Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies

Pharmacodynamics of the novel antifungal agent F901318 for Acute Sinopulmonary Aspergillosis caused by Aspergillus flavus

Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease

In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus

Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans

In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies

Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans

In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim

Review of the novel investigational antifungal olorofim. J Fungi

In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species

In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes

Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei

Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi

Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs

Single-center evaluation of an agar-based screening for azole resistance in Aspergillus fumigatus by using VIPcheck

On the lineage of Aspergillus fumigatus isolates in common laboratory use

Development of a marker-free mutagenesis system using CRISPR-Cas9 in the pathogenic mould Aspergillus fumigatus

EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens. Microb Genom

In vivo efficacy of liposomal amphotericin B against wildtype and azole-resistant Aspergillus fumigatus isolates in two different immunosuppression models of invasive aspergillosis

Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus

Phylogeny, identification and nomenclature of the genus aspergillus

Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis

In-host microevolution of Aspergillus fumigatus: a phenotypic and genotypic analysis

Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis

Molecular tools for the detection and deduction of azole antifungal drug resistance phenotypes in Aspergillus species

Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus

The URA5 gene is necessary for histoplasma capsulatum growth during infection of mouse and human cells

Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans

The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence

Olorofim and the azoles are antagonistic in A. fumigatus and functional genomic screens reveal mechanisms of cross resistance

In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations

In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance

The Aspergillus fumigatus chsC and chsG genes encode class III chitin synthases with different functions

In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management

We thank Norman van Rhijn for discussion about the CRISPR-Cas9 design. 

The study was supported by funding from F2G Ltd.

All data can be requested by the corresponding author upon request.